Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest
Jorge Luis Galeano Niño(The University of Texas at El Paso), Susan Bullman(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael G. White(The University of Texas MD Anderson Cancer Center), Heather Bouzek(Fred Hutch Cancer Center), Martha A. Zepeda‐Rivera(Fred Hutch Cancer Center), Jennifer A. Wargo(Brigham and Women's Hospital), Christopher D. Johnston(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Andrew G. Kempchinsky(Fred Hutch Cancer Center), Falk Ponath(The University of Texas MD Anderson Cancer Center), Ashish Damania(The University of Texas MD Anderson Cancer Center), Pritha Chanana(Fred Hutch Cancer Center), Javier A. Gomez(The University of Texas MD Anderson Cancer Center), Y. Nancy You(The University of Texas MD Anderson Cancer Center), Matthew Wong(The University of Texas MD Anderson Cancer Center), Victor A. Ajisafe(The University of Texas at El Paso), Elizabeth Cromwell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hanrui Wu(Fred Hutch Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Jessica G Terrazas(The University of Texas at El Paso), Nadim J. Ajami(Baylor College of Medicine)
Cited by 18
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k